Oragenics Statistics
Total Valuation
Oragenics has a market cap or net worth of $4.16 million. The enterprise value is $4.40 million.
Important Dates
The next estimated earnings date is Thursday, November 7, 2024, after market close.
Earnings Date | Nov 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Oragenics has 8.66 million shares outstanding. The number of shares has increased by 58.10% in one year.
Shares Outstanding | 8.66M |
Shares Change (YoY) | +58.10% |
Shares Change (QoQ) | +29.55% |
Owned by Insiders (%) | 5.90% |
Owned by Institutions (%) | 4.75% |
Float | 7.32M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 208.60 |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 589.40 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17
Current Ratio | 1.17 |
Quick Ratio | 0.97 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -557.03 |
Financial Efficiency
Return on equity (ROE) is -454.72% and return on invested capital (ROIC) is -277.96%.
Return on Equity (ROE) | -454.72% |
Return on Assets (ROA) | -219.89% |
Return on Capital (ROIC) | -277.96% |
Revenue Per Employee | $1,493 |
Profits Per Employee | -$3.90M |
Employee Count | 5 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.21% in the last 52 weeks. The beta is 0.48, so Oragenics's price volatility has been lower than the market average.
Beta (5Y) | 0.48 |
52-Week Price Change | -84.21% |
50-Day Moving Average | 0.98 |
200-Day Moving Average | 2.22 |
Relative Strength Index (RSI) | 35.51 |
Average Volume (20 Days) | 600,297 |
Short Selling Information
The latest short interest is 1.32 million, so 15.25% of the outstanding shares have been sold short.
Short Interest | 1.32M |
Short Previous Month | 42,738 |
Short % of Shares Out | 15.25% |
Short % of Float | 18.04% |
Short Ratio (days to cover) | 0.95 |
Income Statement
In the last 12 months, Oragenics had revenue of $7,466 and -$19.52 million in losses. Loss per share was -$6.02.
Revenue | 7,466 |
Gross Profit | -13.37M |
Operating Income | -19.66M |
Pretax Income | -19.52M |
Net Income | -19.52M |
EBITDA | -19.64M |
EBIT | -19.66M |
Loss Per Share | -$6.02 |
Full Income Statement Balance Sheet
Cash & Cash Equivalents | 1.35M |
Total Debt | n/a |
Net Cash | 1.35M |
Net Cash Per Share | $0.16 |
Equity (Book Value) | 1.33M |
Book Value Per Share | -0.05 |
Working Capital | 235,646 |
Full Balance Sheet Cash Flow
Operating Cash Flow | -7.21M |
Capital Expenditures | n/a |
Free Cash Flow | -7.21M |
FCF Per Share | -$0.83 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -263,285.20% |
Pretax Margin | -261,401.51% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -95,775.77% |